Top-Rated StocksTop-RatedNASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free ARVN Stock Alerts $32.82 +0.39 (+1.20%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$32.65▼$33.9750-Day Range$31.60▼$48.7952-Week Range$13.57▼$53.08Volume415,374 shsAverage Volume686,050 shsMarket Capitalization$2.24 billionP/E RatioN/ADividend YieldN/APrice Target$59.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arvinas alerts: Email Address Arvinas MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside82.0% Upside$59.73 Price TargetShort InterestBearish13.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$404,489 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.02) to ($4.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector522nd out of 904 stocksPharmaceutical Preparations Industry239th out of 423 stocks 4.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArvinas has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.09% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently increased by 3.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 1.2 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Arvinas this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $404,489.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to grow in the coming year, from ($5.02) to ($4.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About Arvinas Stock (NASDAQ:ARVN)Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Read More ARVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Stock News HeadlinesApril 30, 2024 | theglobeandmail.comAs Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up ResponseApril 26, 2024 | investing.comArvinas appoints new chief business officerMay 5, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 26, 2024 | finanznachrichten.deArvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerApril 24, 2024 | globenewswire.comArvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerApril 20, 2024 | finance.yahoo.comArvinas, Inc. (ARVN)April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth PotentialApril 11, 2024 | investors.comBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsMay 5, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 11, 2024 | markets.businessinsider.comArvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock JumpsApril 11, 2024 | globenewswire.comArvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerMarch 20, 2024 | seekingalpha.comArvinas gets new chief medical officerMarch 19, 2024 | msn.comArvinas gets new chief medical headMarch 18, 2024 | globenewswire.comArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerMarch 4, 2024 | globenewswire.comArvinas to Participate in Upcoming Investor ConferencesMarch 3, 2024 | seekingalpha.comArvinas: Behind The Huge RallyMarch 1, 2024 | finance.yahoo.comArvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?February 28, 2024 | markets.businessinsider.comArvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion into Parkinson’s Disease TreatmentFebruary 28, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN)February 28, 2024 | markets.businessinsider.comNavigating 7 Analyst Ratings For ArvinasFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial HealthFebruary 27, 2024 | benzinga.comArvinas: Q4 Earnings InsightsFebruary 27, 2024 | globenewswire.comArvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 24, 2024 | finance.yahoo.comArvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past weekFebruary 22, 2024 | marketwatch.comArvinas CFO Cassidy to Depart, Teel to Take Over on Interim BasisFebruary 21, 2024 | finance.yahoo.comWhat Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?February 21, 2024 | finanznachrichten.deArvinas Inc.: Arvinas Announces Chief Financial Officer TransitionSee More Headlines Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees445Year FoundedN/APrice Target and Rating Average Stock Price Target$59.73 High Stock Price Target$90.00 Low Stock Price Target$20.00 Potential Upside/Downside+82.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($6.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-367,300,000.00 Net Margins-185.09% Pretax Margin-463.57% Return on Equity-70.24% Return on Assets-31.79% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual Sales$78.50 million Price / Sales28.56 Cash FlowN/A Price / Cash FlowN/A Book Value$11.99 per share Price / Book2.74Miscellaneous Outstanding Shares68,310,000Free Float64,735,000Market Cap$2.24 billion OptionableOptionable Beta1.95 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. John G. Houston Ph.D. (Age 64)Chairperson, CEO & President Comp: $1.08MDr. Ian Taylor Ph.D. (Age 61)Chief Scientific Officer Comp: $692kDr. Randy Teel Ph.D. (Age 44)Interim CFO & Treasurer Mr. David K. Loomis M.B.A. (Age 50)VP, Principal Accounting Officer & Chief Accounting Officer Mr. Jeff BoyleVice President of Investor RelationsMr. Jared M. Freedberg J.D. (Age 55)General Counsel & Corporate Secretary Mr. Steve Weiss (Age 54)Senior VP & Chief Human Resources Officer Dr. John A. Grosso Ph.D. (Age 67)Senior Vice President of R&D Technical Operations Ms. Angela M. Cacace Ph.D. (Age 56)Senior Vice President of Neuroscience & Platform Biology Mr. John P. Northcott (Age 46)Chief Commercial Officer More ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNVera TherapeuticsNASDAQ:VERAGeronNASDAQ:GERNTG TherapeuticsNASDAQ:TGTXDeciphera PharmaceuticalsNASDAQ:DCPHView All CompetitorsInsiders & InstitutionsBI Asset Management Fondsmaeglerselskab A SBought 1,074 shares on 5/3/2024Ownership: 0.002%Nordea Investment Management ABSold 2,255 shares on 5/2/2024Ownership: 0.405%FORA Capital LLCSold 2,333 shares on 5/2/2024Ownership: 0.028%BNP Paribas Financial MarketsSold 49,797 shares on 5/1/2024Ownership: 0.216%Principal Financial Group Inc.Bought 486 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions ARVN Stock Analysis - Frequently Asked Questions Should I buy or sell Arvinas stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks. What is Arvinas' stock price target for 2024? 16 brokers have issued 1-year price targets for Arvinas' stock. Their ARVN share price targets range from $20.00 to $90.00. On average, they expect the company's stock price to reach $59.73 in the next year. This suggests a possible upside of 82.0% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts. How have ARVN shares performed in 2024? Arvinas' stock was trading at $41.16 at the start of the year. Since then, ARVN stock has decreased by 20.3% and is now trading at $32.82. View the best growth stocks for 2024 here. Are investors shorting Arvinas? Arvinas saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,600,000 shares, an increase of 8.6% from the March 15th total of 7,920,000 shares. Based on an average daily volume of 735,200 shares, the days-to-cover ratio is presently 11.7 days. View Arvinas' Short Interest. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) announced its earnings results on Tuesday, February, 27th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($1.15) by $1.38. The company earned ($43.10) million during the quarter, compared to analysts' expectations of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative trailing twelve-month return on equity of 70.24%. During the same period last year, the firm earned ($1.56) EPS. What ETFs hold Arvinas' stock? ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), iShares U.S. Pharmaceuticals ETF (IHE), Zacks Small/Mid Cap Core Portfolio ETF (SMIZ) and Harbor Disruptive Innovation ETF (INNO).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD). When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO. Who are Arvinas' major shareholders? Arvinas' stock is owned by a number of retail and institutional investors. Top institutional investors include Nordea Investment Management AB (0.40%), Wasatch Advisors LP (0.30%), BNP Paribas Financial Markets (0.22%), Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%) and FORA Capital LLC (0.03%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARVN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMysterious Gold Leverage Just AnnouncedStansberry ResearchThe only AI company you should be looking atBehind the MarketsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.